Newsbenzinga
Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity Disorder
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…